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Abstract
The 20S core particle of the proteasome in M. tuberculosis (Mtb) is a promising, yet 
unconventional drug target. This multimeric peptidase is not essential, yet degrades proteins that 
have become damaged and toxic via reactions with nitric oxide (and/or the associated reactive 
nitrogen intermediates) produced during the host immune response. Proteasome inhibitors could 
render Mtb susceptible to the immune system, but they would only be therapeutically viable if 
they do not inhibit the essential 20S counterpart in humans. We designed and synthesized selective 
inhibitors of the Mtb 20S based on both its unique substrate preferences and the structures of 
substrate-mimicking covalent inhibitors of eukaryotic proteasomes called syringolins. Unlike the 
parent syringolins, the designed analogs weakly inhibit the human 20S (Hs 20S) proteasome and 
preferentially inhibit Mtb 20S over the human counterpart by as much as 74-fold. Moreover, they 
can penetrate the mycobacterial cell envelope and render Mtb susceptible to nitric oxide-mediated 
stress. Importantly, they do not inhibit the growth of human cell lines in vitro and thus may be 
starting points for tuberculosis drug development.
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Mycobacterium tuberculosis (Mtb), the deadliest bacterial pathogen, is increasingly 
dangerous because of drug resistance and is thus the focus of drug-development 
programs.1,2 Among recently identified potential drug targets of Mtb, the 20S peptidase of 
the proteasome (Mtb 20S) is unusual.3,4 It is distinct from many drug targets in that it is only 
conditionally required for viability. Mtb mutants lacking the enzyme are viable in vitro, but 
cannot sustain an infection in an animal model of tuberculosis.3 Within mammalian hosts, 
Mtb 20S is essential for the bacterium to survive exposure to the nitric oxide produced by 
macrophages and other cells of the innate immune system.3,4 Presumably, proteins that 
could become toxic via damage by reactions with either nitric oxide or the reactive nitrogen 
intermediates derived from it are targeted for proteasome-mediated degradation via a post-
translational modification with the prokaryotic ubiquitin-like protein, the functional 
equivalent of ubiquitin in eukaryotes.5 This presumption has been validated by reports that 
Mtb 20S inhibitors, like null mutations in the proteasome gene, sensitize Mtb to nitric 
oxide.3,6–9 This chemical validation gives credence to an unconventional pharmacological 
strategy in which small molecules are not used to kill Mtb, but to render it susceptible to the 
immune response.
A potential liability of this strategy for pharmacologically intervening in the host-pathogen 
interaction is that Mtb 20S is similar in structure to and has the same catalytic mechanism as 
the essential human 20S.3,6–9 Indeed, the 20S peptidases of Mtb and eukaryotes share a 
barrel-shaped α7β7β7α7 structure and have a catalytic, N-terminal threonine residue. 
Though they are structurally related, the catalytic β-subunits in eukaryotes have three 
different isoforms exhibiting distinct substrate specificities, while those in the Mtb are 
identical.10,11 In analogy to anti-cancer drugs that inhibit human 20S, Mtb 20S inhibitors 
could be therapeutic agents for tuberculosis.10,11 However, inhibitors of the Mtb 20S will 
only have the safety profile for therapeutic use if they are species-selective.
Progress towards the development of selective inhibitors of Mtb 20S has been enabled by 
knowledge of the unique substrate preferences7 and structural features9 of the enzyme. 
Reflecting the peculiarities of its S1 and S3 pockets, Mtb 20S strongly prefers substrates 
with a bulky tryptophan residue at the P1 position and either glycine or proline at the P3 
position, respectively.7,9,12 With this information, an analog of the proteasome inhibiting 
cancer drug Bortezomib (Velcade) having a meta-chlorobenzyl moiety mimicking the 
preferred substrate’s tryptophan residue at P1 was designed and reported to be an 8-fold 
selective inhibitor of Mtb 20S.7 By extension, we proposed that molecules mimicking both 
the P1 and P3 residues of the enzyme’s preferred substrates would be even more selective. 
We then examined the structures of peptidomimetic 20S inhibitors from the cancer drug 
development literature as scaffolds for the design of compounds that could selectively inhibit 
Mtb 20S.13 Our key criteria for scaffold selection were: a covalent mode of inhibition that 
would potentially circumvent the problematic off-target effects of reversible inhibitors like 
Bortezomib14 and a well-defined mode of binding to the proteasome. Hence, we selected the 
syringolin natural products derived from Psuedomonas syringae. (Figure 1).15,16 Their 
enamide moiety undergoes an irreversible conjugate addition with the active site threonine 
of the peptidase.15 In the crystal structure of yeast 20S with a covalently bound syringolin A 
adduct,16 the macrolactam’s isopropyl substituent and the side chain of the valine residue in 
the appendant ureido peptide moiety fit into the S1 and S3 pockets of the active site, 
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respectively.16,17 We reasoned that replacement of the substituents of the macrolactam and 
the ureido peptide moiety with structures that are analogous to the side chains of the amino 
acids at the P1 (i.e., tryptophan) and P3 (i.e., glycine or proline) positions of a preferred Mtb 
20S substrate would yield a species-selective inhibitor (Figure 2). Beyond the structure-
based design considerations, we selected the syringolins because they facilitate the capacity 
of P. syringae to infect plants.15,17 Because these molecules can penetrate the thick cell wall 
of plants, we predicted that analogs would have a high likelihood of traversing the 
notoriously exclusive cell envelope of M. tuberculosis and thus be active against the 
bacterium in vitro and in vivo.
To prepare the envisioned syringolin analogs, we utilized a diversity-oriented, modular 
synthetic scheme inspired by the work of Stephenson18 and Pirrung19 and recently reported 
by us20 (Scheme 1). In addition to macrolactams having a methyl indole moiety like that of 
tryptophan, we prepared compounds having substituted benzyl groups like those of the 
aforementioned, selective inhibitor of Mtb 20S.7 Macrolactams having an unsubstituted 
benzyl group and the isopropyl substituent of the syringolin natural products were prepared 
as negative controls because the Mtb 20S has low turnover rates for substrates with 
phenylalanine and aliphatic amino acids at the P1 position, respectively. The macrolactams 
having various substituents at the R position were functionalized in a convergent fashion 
with uriedo building blocks having various amino acids at the R´ site, mimicking the P3 
residue of the substrate. Though Mtb 20S strongly prefers substrates with proline or glycine 
at this position, we prepared compounds with other amino acids to test the models for 
substrate preference and mimicry. In all of our syringolin analogs (Table 1; Fig. 2), the 
carboxylic acid of the ureido peptide side chain was transformed to a methyl ester, as this 
modification improves bioactivity of syringolin A.21
To assess the potencies and selectivities of the syringolin analogs as proteasome inhibitors, 
we incubated them with either human or Mtb 20S and subsequently measured the rates of 
enzyme-catalyzed hydrolysis of a fluorogenic substrate (Suc-LLVY-AMC). Because this 
substrate is well-behaved and soluble, it is widely used in kinetic analyses of both human 
and Mtb 20S activities. As irreversible inhibitors, the syringolin analogs were expected to 
react with 20S in a time-dependent fashion in enzymatic assays. Thus, various 
concentrations of the inhibitors were added to mixtures of the enzyme and the fluorogenic 
substrate and then the rates of hydrolysis of the fluorogenic substrate were measured 
continuously and used to determine second-order rate constants for inhibition, kin/Ki 
(M−1s−1) (Table 1) (see supporting information). As these measurements reflect the affinity 
of the non-covalent binding (Ki) and the rate of the chemical reaction of the inhibitors with 
the enzyme (kin), direct comparisons of the compounds can be made. Further, the ratios of 
the second-order rate constants for inhibition of the human and Mtb 20S were used to 
calculate the degree of species selectivity.
All syringolin analogs inhibited the catalytic activities of both enzymes, but there were 
distinct reactivity trends that were congruent with the model for peptidomimicry by the 
syringolins and the substrate preferences Mtb 20S (Table 1). As anticipated, replacement of 
the isopropyl substituent on the syringolin B macrolatam (Table 1, compound 1) with 
aromatic moieties (Table 1, compounds 2-12) consistently led to improvements in second-
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order inhibition rates for Mtb 20S. Gratifyingly, the most reactive inhibitor of this enzyme 
had the tryptophan side chain at R (Table 1, compound 12). Though compounds with 
aromatic moieties at R were generally better inhibitors of human 20S, a 127-fold 
improvement in species-selectivity was observed (Table 1, compound 1 vs. 12). However, 
none of these compounds exhibited preferential inhibition of Mtb 20S.
Having established that inclusion of the methyl indole side chain of tryptophan on the 
macrolactam improved selectivity for Mtb 20S, we explored modifications of the amino acid 
in the appendant ureido side-chain substituent (R′ in Figure 2). Importantly and consistent 
with our design strategy, compounds with either proline (Table 1, compound 13) or glycine 
(Table 1, compound 14) at that position preferentially inhibited Mtb 20S- the former and 
latter were 33- and 74-fold selective for the Mtb 20S, respectively. We also note that the 
most selective inhibitor is 220-fold more reactive with Mtb 20S than the parent compound 
(Table 1, compound 1). Surprisingly, a compound designed to mimic a poor substrate of the 
Mtb 20S proteasome (i.e., a peptide with phenylalanine at P3)7 was highly reactive with the 
enzyme; however, it preferentially inhibited the human enzyme (Table 1, compound 16). 
Collectively, these results indicate that the mimic of the substrate’s P3 residue is especially 
important for defining species-selectivity.
To gain further insights into the structure-activity relationships, we carried out additional 
experiments. Because syringolin A, defined by an additional unit of unsaturation in the 
macrolactam, was reportedly more potent than syringolin B,15,16,21–23 we prepared an 
analog of the most selective inhibitor with this moiety and found that it had a higher degree 
of reactivity; it was less species-selective. In addition, we synthesized an analog of our most 
selective inhibitor (Table 1, compound 14) having a N,N-diethyl asparagine side chain at R´ 
(Table 1, compound 17), which was reported as a good P3 mimic in the structure of a highly 
selective N,C-capped dipeptide inhibitor of Mtb 20S.9 We found that this alteration 
dramatically improved potency, but compromised species-selectivity. We also prepared an 
analog of the less selective inhibitor (Table 1, compound 13) with homoproline in place of 
proline (Table 1, compound 18). Apparently, the change in conformation resulting from 
expansion of the ring dramatically reduced both potency and selectivity for inhibition of Mtb 
20S. Finally, because the ureido moiety in all of the syringolins could be important for 
hydrogen bonding to the enzyme, we prepared analogs of our most selective inhibitor (Table 
1, compound 14) with either sarcosine or β-alanine in place of glycine. The former enabled 
assessment of the ureido group’s role as a hydrogen bond donor via its N-methyl group, 
whereas the latter allowed analysis of the ureido group’s position as a hydrogen-bond donor/
acceptor due to its additional methylene. In technically simple yet less precise assays 
wherein the IC50 of the compounds rather than their second-order rate constants of 
inhibition were measured, we found that both modifications compromised potency and 
species-selectivity (data not shown, see supporting information). These observations indicate 
that the structure and position of the ureido moiety are important for the compounds’ 
enzyme binding.
Based on the bioactivity of the syringolins as virulence factors in plants, we predicted that 
the analogs would be able to traverse the highly exclusive peptidoglycan of M. tuberculosis 
and inhibit activity of the cytosolic enzyme. To test this prediction, we treated cultures of 
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Mycobacterium bovis BCG (a non-pathogenic surrogate of M. tuberculosis) with the most 
selective inhibitors of Mtb 20S (Table 1, compound 13 and 14) and then measured the 
proteasome-specific activity using a chromogenic substrate after whole cell lysis (Figure 3). 
While we were gratified to find that the selective inhibitors suppressed the apparent 
proteasome activity, our finding that the lesser selective inhibitor in the proteasome 
inhibition assays (compound 13) was the most active in cells was surprising. We ascribe 
these observations to differences in the compounds’ cell permeability; indeed, compound 13 
(having proline rather than glycine as a P3 mimic) is more lipophilic than compound 14. 
Subsequently, we carried out experiments to determine if the compounds would render non-
replicating Mtb susceptible to nitric oxide in a dose-dependent fashion.3,8,9 As anticipated, 
the inhibitors exhibited a dose-dependent bactericidal effect in media supplemented with a 
source of nitric oxide and had little toxicity in the absence of nitric oxide wherein 
proteasome activity is not essential for viability (Figure 4). Negative results observed with 
compound 13sat (in which the reactive α,β-enamide required for covalent inhibition had 
been chemically inactivated by reduction) confirmed the inhibitors’ mode of action. Though 
both inhibitors effected dose-dependent susceptibility of Mtb to sodium nitrite, the 
bactericidal activity of compound 13 plateaued at a higher concentration than compound 14 
for reasons that are not obvious (Figure 4). Nevertheless, compound 14, the most potent and 
selective inhibitor of Mtb 20S in vitro, was the most efficacious in sensitizing the bacterium 
to nitrosative stress. In fact, at the highest concentration tested (50 μM), this compound 
effected a three-order of magnitude reduction in the number of colony forming units (CFU) 
on media supplemented with sodium nitrite (Figure 4).
Because the selective inhibitors of Mtb 20S had low reactivity with human 20S, we 
predicted that they would not have the parent compound’s toxicity to human cells (Table 1, 
compounds 1, 13, and 14). Indeed, we found that, unlike compound 1 (syringolin B methyl 
ester), compounds 13 and 14 were not toxic to the HepG2 human liver carcinoma cell line at 
concentrations as high as 50 μM (see supporting information). Syringolin B methyl ester and 
compound 14 were further tested against the National Cancer Institute panel of sixty human 
cancer cell lines. The mean growth in the presence of compound 14 at 10 μM compared to 
that of the untreated controls was 102%. In contrast, cancer cells exposed to syringolin B 
methyl ester at the same concentration exhibited 27% of the growth of the cells that were 
only treated with the vehicle (see supporting information).
Here, we report the rational design and syntheses of species-selective inhibitors of Mtb 20S 
based on the enzyme’s substrate preferences and the proposed mode by which the 
syringolins bind the eukaryotic proteasome. Our approach stands in marked contrast to 
previous reports in which highly selective inhibitors of Mtb 20S were identified via high-
throughput screening.8,9 Though the oxathiazolones and the N,C-capped dipeptides 
discovered via those high-throughput screening efforts were highly selective (~1300 and 
~4,600-fold, respectively) and bioactive, their development into first-in-class tuberculosis 
drug leads is contingent on optimization of their pharmacological properties. The efforts 
described herein were motivated by a need to fill this innovation gap in the development of 
tuberculosis drugs that act via intervention in the host-pathogen interaction. Remarkably, we 
achieved an absolute inversion in the syringolins’ inherent species-selectivity that was 
accompanied by the virtual elimination of parent compounds’ toxicity to human cells. 
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Relative to the inhibitory parameters of the syringolin B natural product, our most selective 
inhibitor has a 250-fold improved rate of reaction with Mtb 20S and a 99.6% lower rate of 
reaction with human 20S. Beyond being the first time that a natural product structure was 
used in the design of a species-selective proteasome inhibitor, our findings are noteworthy 
because the species-selectivity of our best inhibitor (74-fold preference for Mtb 20S) and the 
degree of change in species-selectivity relative to the starting scaffold (syringolin B has a 
160-fold preference for Hs 20S) are markedly superior to those achieved in the previous 
report of structure-based design.7 In that case, only 8-fold selectivity for Mtb 20S inhibition 
was attained by applying the substrate-guided design strategy to the structure of the cancer 
drug bortezomib (a synthetic peptide boronate having an 18-fold preference for reversible 
inhibition of human 20S).7 More broadly, we note that this substrate-guided design strategy 
could be applied to most known eukaryotic 20S inhibitors. In fact, it has been recently 
applied to vinyl sulfones for the development of species-selective inhibitors of the 20S 
enzyme in Plasmodium falciparum, the causative agent of malaria.24 In any case, our 
findings validate the peptidomimetic model for enzyme inhibition by the syringolins, 
provide further validation for the use of Mtb 20S inhibitors as selective bactericidal agents, 
and justify rational design as an alternative to the high-throughput screening methods that 
have previously been used to identify selective inhibitors of Mtb 20S.10,11 Efforts are now 
underway to characterize the pharmacokinetic/pharmacodynamic properties of these 
inhibitors, to further optimize their structures, and to assess their efficacies in animal models 
of tuberculosis.
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Figure 1. 
Chemical structures of syringolin A (SylA) and syringolin B (SylB) proteasome inhibitors.15
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Figure 2. 
Structural model for proteasome substrate mimicry by the syringolins. Substituents at R and 
R′ correspond to P1 and P3 residues of a peptide substrate, respectively.
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Figure 3. 
Evaluating the cell permeability and activity of selective Mtb 20S inhibitors using M. bovis 
BCG. Apparent activity reflects proteasome-activity observed in lysates from the treated and 
untreated cultures. The proteasome activity observed in the untreated sample was set as 
100%. The experiments were performed in triplicate. See supporting information for 
experimental protocols.
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Figure 4. 
Mtb nitric-oxide stress assays for compound 14. 0 μM experiment indicates CFU/mL value 
of DMSO control experiment. The lightly colored bars show CFU counts in assays lacking 
NaNO2. Assays were performed in triplicate. See supporting information for protocol.
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Scheme 1. 
Synthesis of syringolin analogs.18–20
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